Denmark - HealthQuill

One to five years of antidepressant usage, increases the risk of sudden cardiac death by 56%, according to a Danish study, which found that the risk more than doubles in those using for six years and above.

Antidepressant use for upto 5 years ups sudden cardiac death by 56%

HQ Team April 1, 2025: One to five years of antidepressant usage, increases the risk of sudden cardiac death by 56%, according to.

by HealthQuill
March 31, 2025
0 Comments

Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and commercialising of the Chinese company’s “triple G” weight-loss candidate.

Drugs Medical Pharma

Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug

HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.

by HealthQuill
March 25, 2025
0 Comments

AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services and peptide-based drug discovery, for about $2.2 billion to mark its entry into the obesity treatment space.

Drugs Medical Pharma

AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market

HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.

by HealthQuill
March 4, 2025
0 Comments

Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular disease in diabetic adults with chronic kidney disease.

Drugs Health Medical

Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod

Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.

by HealthQuill
January 29, 2025
0 Comments

Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs to be jointly developed, according to a statement.

Drugs Health Medical

Novo Nordisk, Valo expand pact to include obesity, diabetic drugs

Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs.

by HealthQuill
January 9, 2025
0 Comments

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without worsening the condition.

Drugs Health Pharma

Novo Nordisk’s weight loss drug reduces live scarring in end-stage trial

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.

by HealthQuill
November 2, 2024
0 Comments

Uric acid may emerge as a potential therapy to treat ischemic stroke after US researchers discovered a new method in studies on animals.

Drugs Health Medical

Danish study reveals half of patients with sepsis die within two years

HQ Team October 15, 2024: Severe sepsis and septic shock are major causes of mortality in intensive care unit (ICU) patients. According to.

by HealthQuill
October 15, 2024
0 Comments

H. Lundbeck A/S, a Danish drugmaker, plans to acquire California, US-based Longboard Pharmaceuticals for $2.6 billion, giving it access to a late-stage drug to treat seizures in a group of rare epilepsies.

Drugs Health Pharma

Lundbeck targets epileptic drug, to buy Longboard for $2.6 billion

H. Lundbeck A/S, a Danish drugmaker, plans to acquire California, US-based Longboard Pharmaceuticals for $2.6 billion, giving it access to a late-stage drug.

by HealthQuill
October 14, 2024
0 Comments

https://investor.g1therapeutics.com/news-releases/news-release-details/fda-approves-g1-therapeutics-coselatm-trilaciclib-first-and-only

Drugs Health Pharma

Denmark’s Pharmacosmos to buy G1 Therapeutics for $405 million

Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.